Plus Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $1,397 | $1,390 | $1,059 | $1,412 |
Gross Profit | 1,311 | 1,304 | 878 | 1,180 |
EBITDA | -4,337 | 5,272 | -13,461 | -3,614 |
EBIT | -4,423 | 5,151 | -13,642 | -3,846 |
Net Income | -4,423 | 5,151 | -17,401 | -3,903 |
Net Change In Cash | 1,397 | 1,390 | 1,059 | 1,412 |
Free Cash Flow | -2,575 | -5,805 | -6,175 | -1,222 |
Cash | 13,289 | 2,233 | 9,867 | 76 |
Basic Shares | 1,074,289 | 209,154 | 14,567 | 5,896 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $5,824 | $4,913 | $224 | $0 |
Gross Profit | 4,972 | -4,777 | -488 | -66 |
EBITDA | -8,402 | -12,693 | -18,852 | -12,048 |
EBIT | -9,254 | -13,321 | -19,564 | -12,467 |
Net Income | -12,978 | -13,316 | -20,275 | -13,399 |
Net Change In Cash | 5,824 | 4,913 | 224 | 0 |
Free Cash Flow | -10,700 | -13,011 | -13,731 | -10,424 |
Cash | 76 | 8,554 | 18,120 | 18,400 |
Basic Shares | 7,701 | 3,140 | 1,750 | 805 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.04 |
2025-06-30 | -$0.006 |
2025-03-31 | -$0.56 |
2024-12-31 | -$0.49 |
